CompletedPhase 4

Hypotension in the Weaning From Vasopressor Drugs

Brazil78 participantsStarted 2022-05-01

Plain-language summary

Although there is consensus in the literature on hemodynamic management of septic shock in the resuscitation phase, the best way to conduct the weaning of vasopressor drugs in the stabilization phase remains open. The present study aims to study the incidence of hypotension in the weaning phase of vasopressor drugs- norepinephrine and vasopressin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with septic shock, according to the definitions of SEPSIS - 3: septic and hypotensive patients, demanding use of vasoactive drug and lactate greater than 2 mmol/L (18 mg/dL). * Patients admitted to the intensive care unit. * Patients in need of associated use of norepinephrine and vasopressin. Exclusion Criteria: * Patients in whom discontinuation of norepinephrine or vasopressin has been given by decision of the assistant team, from a perspective of prioritizing palliative care. * Patients using a combination of a third drug, with the effect of predominantly vasopressor - adrenaline.

What they're measuring

Incidence of hypotension

Timeframe: The first 24 hours after the start of reduction of one of the vasopressors.

Trial details

NCT IDNCT05506319

SponsorHospital Nossa Senhora da Conceicao

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-01

View on ClinicalTrials.gov More Septic Shock trials